Aardvark Therapeutics (AARD) Accounts Payables (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Accounts Payables data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 75.78% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (up 75.78% YoY), and the FY2025 full-year result was $2.1 million, down 9.83% from the prior year.
• Accounts Payables improved to $4.5 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.1 million in Q2 2025 to a low of $2.1 million in Q4 2025.
• A 3-year average of $3.5 million and a median of $3.5 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables dropped 9.83% in 2025 and surged 75.78% in 2026, its largest moves.
• Tracing AARD's Accounts Payables over 3 years: stood at $2.3 million in 2024, then dropped by 9.83% to $2.1 million in 2025, then surged by 116.84% to $4.5 million in 2026.
• Business Quant data shows AARD's Accounts Payables at $4.5 million in Q1 2026, $2.1 million in Q4 2025, and $4.4 million in Q3 2025.